BidaskClub upgraded shares of Vital Therapies, Inc. (NASDAQ:VTL) from a buy rating to a strong-buy rating in a report released on Thursday.

Separately, Zacks Investment Research downgraded shares of Vital Therapies from a hold rating to a sell rating in a research note on Thursday. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Hold and an average target price of $8.00.

Vital Therapies (NASDAQ VTL) traded down 2.48% during trading on Thursday, hitting $5.90. The company had a trading volume of 112,274 shares. Vital Therapies has a one year low of $2.25 and a one year high of $6.58. The stock has a 50-day moving average of $3.99 and a 200-day moving average of $3.43. The stock’s market capitalization is $249.02 million.

Vital Therapies (NASDAQ:VTL) last issued its earnings results on Thursday, August 3rd. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.01. During the same quarter last year, the company earned ($0.30) earnings per share. On average, equities analysts anticipate that Vital Therapies will post ($1.31) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/10/06/vital-therapies-inc-vtl-upgraded-to-strong-buy-by-bidaskclub.html.

In related news, Director Jean Jacques Bienaime acquired 10,000 shares of the business’s stock in a transaction on Wednesday, September 13th. The stock was purchased at an average cost of $4.00 per share, for a total transaction of $40,000.00. Following the completion of the transaction, the director now directly owns 65,119 shares of the company’s stock, valued at approximately $260,476. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Muneer A. Satter acquired 50,000 shares of the business’s stock in a transaction on Friday, September 8th. The shares were bought at an average price of $3.53 per share, with a total value of $176,500.00. The disclosure for this purchase can be found here. Insiders purchased a total of 190,000 shares of company stock valued at $737,800 over the last quarter. 32.60% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of VTL. SG Americas Securities LLC acquired a new stake in Vital Therapies during the first quarter worth approximately $167,000. Goldman Sachs Group Inc. lifted its position in Vital Therapies by 1.8% during the first quarter. Goldman Sachs Group Inc. now owns 64,545 shares of the company’s stock worth $258,000 after acquiring an additional 1,157 shares during the last quarter. Susquehanna International Group LLP acquired a new stake in Vital Therapies during the second quarter worth approximately $268,000. Blair William & Co. IL lifted its position in Vital Therapies by 67.2% during the second quarter. Blair William & Co. IL now owns 99,500 shares of the company’s stock worth $289,000 after acquiring an additional 40,000 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Vital Therapies by 11.5% during the first quarter. Bank of New York Mellon Corp now owns 88,104 shares of the company’s stock worth $352,000 after acquiring an additional 9,120 shares during the last quarter. Hedge funds and other institutional investors own 25.58% of the company’s stock.

Vital Therapies Company Profile

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Receive News & Stock Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related stocks with our FREE daily email newsletter.